Drug combination therapy increases successful drug repositioning.

[1]  Rachel M. Webster.  Combination therapies in oncology , 2016, Nature Reviews Drug Discovery.

[2]  Chih-Ming Ho,et al.  Optimization of drug combinations using Feedback System Control , 2016, Nature Protocols.

[3]  Yi-Cheng Tu,et al.  A novel algorithm for analyzing drug-drug interactions from MEDLINE literature , 2015, Scientific Reports.

[4]  M. Reich,et al.  Essential medicines are still essential , 2015, The Lancet.

[5]  Mohieddin Jafari,et al.  Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database , 2015, Briefings Bioinform..

[6]  A. Butte,et al.  Relating Chemical Structure to Cellular Response: An Integrative Analysis of Gene Expression, Bioactivity, and Structural Data Across 11,000 Compounds , 2015, CPT: pharmacometrics & systems pharmacology.

[7]  Gang Zhao,et al.  Metformin and temozolomide act synergistically to inhibit growth of glioma cells and glioma stem cells in vitro and in vivo , 2015, Oncotarget.

[8]  Sam Michael,et al.  High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations , 2015, Scientific Reports.

[9]  M. Schuemie,et al.  The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. , 2015, British journal of clinical pharmacology.

[10]  R. Minter,et al.  Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling , 2015, Molecular Cancer.

[11]  Luca Pinzi,et al.  Computational polypharmacology comes of age , 2015, Front. Pharmacol..

[12]  C. Lindsley.  2014 prescription medications in the United States: tremendous growth, specialty/orphan drug expansion, and dispensed prescriptions continue to increase. , 2015, ACS chemical neuroscience.

[13]  S. Strittmatter,et al.  Fyn inhibition rescues established memory and synapse loss in Alzheimer mice , 2015, Annals of neurology.

[14]  Kewei Chen,et al.  A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease , 2015, Alzheimer's Research & Therapy.

[15]  Asher Mullard.  2014 FDA drug approvals , 2015, Nature Reviews Drug Discovery.

[16]  Gisbert Schneider,et al.  Multidimensional de novo design reveals 5-HT2B receptor-selective ligands. , 2015, Angewandte Chemie.

[17]  Sridhar Ramaswamy,et al.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer , 2014, Science.

[18]  I. Chumakov,et al.  An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A , 2014, Orphanet Journal of Rare Diseases.

[19]  David S. Goodsell,et al.  The RCSB Protein Data Bank: views of structural biology for basic and applied research and education , 2014, Nucleic Acids Res..

[20]  M. Kollef,et al.  Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study , 2014, Critical Care.

[21]  George Hripcsak,et al.  Similarity-based modeling in large-scale prediction of drug-drug interactions , 2014, Nature Protocols.

[22]  D. Kwiatkowski,et al.  Spread of artemisinin resistance in Plasmodium falciparum malaria. , 2014, The New England journal of medicine.

[23]  F. Buckner,et al.  Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi , 2014, PLoS neglected tropical diseases.

[24]  M. Markowitz,et al.  A Randomized Open-Label Study of 3- Versus 5-Drug Combination Antiretroviral Therapy in Newly HIV-1–Infected Individuals , 2014, Journal of acquired immune deficiency syndromes.

[25]  Stephen T. C. Wong,et al.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.

[26]  Petra Schneider,et al.  Multi-objective molecular de novo design by adaptive fragment prioritization. , 2014, Angewandte Chemie.

[27]  Robert H. Brown,et al.  Intrinsic membrane hyperexcitability of amyotrophic lateral sclerosis patient-derived motor neurons. , 2014, Cell reports.

[28]  L. Peshkin,et al.  Exploiting polypharmacology for drug target deconvolution , 2014, Proceedings of the National Academy of Sciences.

[29]  J. Walochnik,et al.  Miltefosine and polyhexamethylene biguanide: a new drug combination for the treatment of Acanthamoeba keratitis , 2014, Clinical & experimental ophthalmology.

[30]  Ruili Huang,et al.  Chemical signatures and new drug targets for gametocytocidal drug development , 2014, Scientific Reports.

[31]  Paul Shinn,et al.  Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs , 2014, Emerging Microbes & Infections.

[32]  N. Sadrieh,et al.  A novel QSAR model of Salmonella mutagenicity and its application in the safety assessment of drug impurities. , 2013, Toxicology and applied pharmacology.

[33]  Wei Zheng,et al.  Phenotypic screens as a renewed approach for drug discovery. , 2013, Drug discovery today.

[34]  G. Everson,et al.  Drug–drug interactions during antiviral therapy for chronic hepatitis C , 2013, Nature Reviews Gastroenterology &Hepatology.

[35]  Natsuyo Aoyama,et al.  Phenotypic Screening with Human iPS Cell–Derived Cardiomyocytes , 2013, Journal of biomolecular screening.

[36]  C. Austin,et al.  Identification of Therapeutic Candidates for Chronic Lymphocytic Leukemia from a Library of Approved Drugs , 2013, PloS one.

[37]  Jun O. Liu,et al.  Phase 2 Study of Pemetrexed and Itraconazole as Second-Line Therapy for Metastatic Nonsquamous Non–Small-Cell Lung Cancer , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  M L Bolognesi,et al.  Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.

[39]  J. Karlowsky,et al.  Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination , 2013, Drugs.

[40]  Christopher P Austin,et al.  High-Throughput Multiplexed Quantitation of Protein Aggregation and Cytotoxicity in a Huntington’s Disease Model , 2012, Current chemical genomics.

[41]  U. Baxa,et al.  δ-Tocopherol Reduces Lipid Accumulation in Niemann-Pick Type C1 and Wolman Cholesterol Storage Disorders* , 2012, The Journal of Biological Chemistry.

[42]  Xu Han,et al.  Literature Based Drug Interaction Prediction with Clinical Assessment Using Electronic Medical Records: Novel Myopathy Associated Drug Interactions , 2012, PLoS Comput. Biol..

[43]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[44]  M. Borad,et al.  Phase I Study of Bosutinib, a Src/Abl Tyrosine Kinase Inhibitor, Administered to Patients with Advanced Solid Tumors , 2011, Clinical Cancer Research.

[45]  X. Su,et al.  Chemical Genomic Profiling for Antimalarial Therapies, Response Signatures, and Molecular Targets , 2011, Science.

[46]  M. Manns,et al.  Second-wave protease inhibitors: choosing an heir. , 2011, Clinics in liver disease.

[47]  D. Swinney,et al.  How were new medicines discovered? , 2011, Nature Reviews Drug Discovery.

[48]  Shinichiro Okamoto,et al.  Successful treatment of adult onset Langerhans cell histiocytosis with multi-drug combination therapy. , 2011, Internal medicine.

[49]  Ruili Huang,et al.  The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics , 2011, Science Translational Medicine.

[50]  Clive N. Svendsen,et al.  Human stem cells and drug screening: opportunities and challenges , 2010, Nature Reviews Drug Discovery.

[51]  Peter C Austin,et al.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study , 2010, BMJ : British Medical Journal.

[52]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[53]  May Ho,et al.  Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs , 2010, Nature Genetics.

[54]  Xiaohua Ma,et al.  Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.

[55]  Jun O. Liu,et al.  Inhibition of angiogenesis by the antifungal drug itraconazole. , 2007, ACS chemical biology.

[56]  Dan C. Fara,et al.  Lead-like, drug-like or “Pub-like”: how different are they? , 2007, J. Comput. Aided Mol. Des..

[57]  S. Frantz.  The trouble with making combination drugs. , 2006, Nature reviews. Drug discovery.

[58]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[59]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[60]  Jun O. Liu,et al.  A clinical drug library screen identifies astemizole as an antimalarial agent , 2006, Nature chemical biology.

[61]  M. MacDonald,et al.  Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation , 2005, BMC Neuroscience.

[62]  David A. Flockhart,et al.  CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.

[63]  Péter Csermely,et al.  The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.

[64]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[65]  D. Ho,et al.  Time to hit HIV, early and hard. , 1995, The New England journal of medicine.

[66]  N. Gulbahce,et al.  Network medicine: a network-based approach to human disease , 2010, Nature Reviews Genetics.